Skip to main content
. Author manuscript; available in PMC: 2019 Dec 10.
Published in final edited form as: Med Hypotheses. 2018 Jun 5;117:63–68. doi: 10.1016/j.mehy.2018.06.004

Figure.

Figure.

Pathway to chronic rapamycin therapy in prostate cancer

Model: Chronic mTORC1 inhibition delays of PCa progression from active surveillance. mTORC1 and its downstream effectors promote tumor-cell growth (progression) in response to anabolic stimuli. Chronic inhibition of mTORC1 by drugs such as rapamycin would theoretically reduce the probability of conversion to Hi-grade PCa.